Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis

• Main Authors: Hiroaki Kanzaki (Author), Sadahisa Ogasawara (Author), Tomomi Okubo (Author), Norio Itokawa (Author), Ryohei Yoshino (Author), Kentaro Fujimoto (Author), Tadayoshi Kogure (Author), Sae Yumita (Author), Takamasa Ishino (Author), Keita Ogawa (Author), Terunao Iwanaga (Author), Miyuki Nakagawa (Author), Kisako Fujiwara (Author), Ryuta Kojima (Author), Keisuke Koroki (Author), Masanori Inoue (Author), Kazufumi Kobayashi (Author), Naoya Kanogawa (Author), Soichiro Kiyono (Author), Masato Nakamura (Author), Takayuki Kondo (Author), Ryo Nakagawa (Author), Shingo Nakamoto (Author), Ryosuke Muroyama (Author), Ei Itobayashi (Author), Masanori Atsukawa (Author), Jun Kato (Author), Naoya Kato (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Cabozantinib was found to be effective as a second- or third-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) in the phase 3 CELESTIAL trial. So far, as immunotherapy has substituted molecular target agents as the primary systemic therapy fo...